Celularity Inc
CELU3.184USD
+0.064+2.05%
交易中 （美东）报价延迟15分钟
71.79M总市值
亏损市盈率 TTM
关于 Celularity Inc 公司
Celularity Inc. 是一家再生和细胞医学公司。该公司正在开发和商业化先进的生物材料产品和同种异体、冷冻保存、胎盘衍生细胞疗法，这些疗法均源自产后胎盘。该公司的治疗计划针对衰老相关疾病，包括退行性疾病、癌症和免疫疾病，使用间充质样粘附基质细胞、用 CAR 改造的 T 细胞（CAR T 细胞）以及转基因和未转基因的自然杀伤 (NK) 细胞。该公司开发、制造和商业化源自产后胎盘组织（包括脐带）结构组织成分的先进生物材料产品。其先进的生物材料包括 Celularity 肌腱包裹物、FUSE 骨空隙填充物和 Celularity 胎盘基质。其先进的生物材料产品包括 Biovance、Interfyl 和 Rebound 产品。其平台是Celularity IMPACT（免疫调节胎盘衍生同种异体细胞疗法）。
公司简介
公司代码CELU
公司名称Celularity Inc
上市日期May 23, 2019
CEODr. Robert J. (Bob) Hariri, M.D., Ph.D.
员工数量123
证券类型Ordinary Share
年结日May 23
公司地址170 Park Ave
城市FLORHAM PARK
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编07932
电话19087682170
网址https://celularity.com/
公司代码CELU
上市日期May 23, 2019
CEODr. Robert J. (Bob) Hariri, M.D., Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.85M
+0.12%
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. John R. Haines
Mr. John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
--
--
Mr. Joseph Dossantos
Mr. Joseph Dossantos
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Mr. Carlos Ramirez
Mr. Carlos Ramirez
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
Mr. Vincent Levien
Mr. Vincent Levien
Director
Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.85M
+0.12%
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. John R. Haines
Mr. John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月2日 周六
更新时间: 8月2日 周六
持股股东
股东类型
持股股东
持股股东
占比
Genting Bhd
26.45%
Hariri (Robert J)
11.92%
Starr International Company, Inc.
6.38%
Celgene Corporation
4.99%
Lung Biotechnology Inc
3.33%
Other
46.93%
持股股东
持股股东
占比
Genting Bhd
26.45%
Hariri (Robert J)
11.92%
Starr International Company, Inc.
6.38%
Celgene Corporation
4.99%
Lung Biotechnology Inc
3.33%
Other
46.93%
股东类型
持股股东
占比
Corporation
36.88%
Individual Investor
14.45%
Investment Advisor
9.43%
Insurance Company
3.19%
Investment Advisor/Hedge Fund
1.17%
Hedge Fund
0.35%
Research Firm
0.30%
Bank and Trust
0.20%
Venture Capital
0.04%
Other
33.99%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
104
15.81M
66.01%
-1.35M
2025Q1
140
16.18M
70.80%
+52.81K
2024Q4
156
14.05M
63.43%
-1.62M
2024Q3
169
14.41M
66.16%
-2.07M
2024Q2
181
15.12M
69.86%
-663.91K
2024Q1
187
14.36M
66.56%
-1.48M
2023Q4
186
12.31M
65.02%
-347.56K
2023Q3
186
12.52M
68.51%
+23.28K
2023Q2
200
12.33M
70.15%
-1.64M
2023Q1
224
13.36M
90.76%
-717.66K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Genting Bhd
6.34M
26.45%
--
--
May 15, 2025
Hariri (Robert J)
2.85M
11.92%
+3.28K
+0.12%
May 15, 2025
Starr International Company, Inc.
1.53M
6.38%
--
--
May 15, 2025
Celgene Corporation
1.20M
4.99%
--
--
Feb 07, 2025
Lung Biotechnology Inc
796.88K
3.33%
--
--
Dec 31, 2023
C.V. Starr & Co., Inc.
764.07K
3.19%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
500.13K
2.09%
--
--
Mar 31, 2025
Kehler (Dean C)
281.94K
1.18%
--
--
Feb 07, 2025
Geode Capital Management, L.L.C.
136.04K
0.57%
+4.53K
+3.45%
Mar 31, 2025
Diamandis (Peter)
134.31K
0.56%
-63.82K
-32.21%
May 15, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Micro-Cap ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
占比0%
iShares Micro-Cap ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Feb 23, 2024
Merger
10<1
Feb 23, 2024
Merger
10<1
Feb 23, 2024
Merger
10<1
Feb 23, 2024
Merger
10<1
公告日期
类型
比率
Feb 23, 2024
Merger
10<1
Feb 23, 2024
Merger
10<1
Feb 23, 2024
Merger
10<1
Feb 23, 2024
Merger
10<1
